{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45","upperLimit":"73","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"1 yr Extensive Chronic GVHD\n\nSummarized using standard descriptive statistics along with corresponding 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan\\* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.\n\nNote: \\*Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.","id":"OG000","title":"Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible who survived to day 100 and were eligible to get chronic GVHD","reportingStatus":"POSTED","timeFrame":"Up to 4.5 years","title":"1 yr Extenstive Chronic GVHD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}